MEDFORD, N.Y., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences.
Management is scheduled to present at the Canaccord Genuity MedTech & Diagnostics Forum in New York, New York on Thursday, November 21, 2019 at 3:00 pm ET. Interested parties may access a live or recorded webcast of the presentation on the “Investor” section of the company’s website at www.chembio.com.
Management is also scheduled to participate in the Benchmark Discovery One-on-One Conference in New York, New York on Wednesday, December 4, 2019. Due to the format of this event no webcast is available.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease, a number of which applications are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to its trademark.
|Lynn Pieper Lewis |